Femoral Artery News and Research

RSS

Transcatheter valve replacement safe and effective alternative to open-heart surgery

An innovative approach for implanting a new aortic heart valve without open-heart surgery is being offered at Rush University Medical Center to patients with severe aortic stenosis who are at high-risk or not suitable candidates for open heart valve replacement surgery.

27 Jun 2011

Zilver PTX stent more effective than PTA for treatment of femoral artery lesions

Results of a prospective, randomized trial indicate that when treating femoral artery (SFA) lesions, the Zilver PTX Paclitaxel-Eluting Stent shows sustained effectiveness compared to percutaneous transluminal angioplasty, even in diabetic patients.

20 Jun 2011

Heart function may be affected in people with Type 2 diabetes as early as adolescence

Heart function may be affected in people with Type 2 diabetes as early as adolescence, according to a new study that will be presented Sunday at The Endocrine Society's 93rd Annual Meeting in Boston.

8 Jun 2011

First human implant of St. Jude Medical's Portico transcatheter aortic heart valve

St. Jude Medical, Inc., a global medical device company, today announced the first human implant of its Portico transcatheter aortic heart valve. The procedure was performed by Dr. John Webb, director of cardiac catheterization and interventional cardiology at St. Paul's Hospital in Vancouver, British Columbia.

7 Jun 2011

FDA grants Pathway marketing clearance for JETSTREAM Navitus revascularization catheter for PVD

Pathway Medical Technologies, Inc, an innovator of endovascular treatments for peripheral vascular disease (PVD), announced today that the U.S. Food and Drug Administration (FDA) has granted the company 510(k) clearance to market JETSTREAM Navitus, an enhanced revascularization catheter for the treatment of PVD.

6 Jun 2011

IDEV completes enrollment in SUPERA stent trial for treatment of peripheral artery disease

IDEV Technologies, Inc. today announced the completion of enrollment in the SUPERB Trial, an FDA-approved IDE trial evaluating the use of IDEV's SUPERA stent system for treatment of peripheral artery disease in the superficial femoral artery.

3 Jun 2011

Medtronic issues statement on results of CoreValve System clinical data presented at EuroPCR 2011

Medtronic, Inc. today issued a statement on results of clinical data presented at EuroPCR 2011 that show the Medtronic CoreValve System, delivered through a new approach beneath the collarbone, achieved excellent procedural success rates and low in-hospital complication rates.

From Medtronic 19 May 2011

Medtronic to present new clinical results on innovative medical devices at EuroPCR

New clinical data on a range of innovative medical devices from Medtronic, Inc., to treat cardiac and vascular diseases - from severe aortic stenosis and uncontrolled hypertension, to coronary and peripheral artery disease - will be presented next week at EuroPCR. Many of the presentations will be featured during late-breaking sessions at this large international interventional cardiology meeting, which takes place in Paris from May 17-20.

From Medtronic 12 May 2011

Boston Scientific initiates clinical enrollment for INNOVA Self-Expanding Bare-Metal Stent System trial

Boston Scientific Corporation today announced the start of patient enrollment in the SuperNOVA clinical trial, an international, prospective, single-arm, non-randomized trial evaluating the safety and effectiveness of the INNOVA™ Self-Expanding Bare-Metal Stent System in patients with stenosis of the superficial femoral artery (SFA) or proximal popliteal artery (PPA).

6 Apr 2011

Less-invasive catheter-based aortic valve replacement as safe and effective as open surgery

Less-invasive catheter-based aortic valve replacement has a similar one-year survival as open valve-replacement surgery for patients at high risk for surgery.

5 Apr 2011

SMT announces $10.5 million financing to develop novel device for use in TAVI procedures

SMT Research and Development Ltd. of Herzliya Pituach, Israel announced today a significant investment by OrbiMed Advisors LLC. SMT is finalizing the development of a novel embolic protection device designed for use during Transcatheter Aortic Valve Implantation procedures.

4 Apr 2011

Prostatic artery embolization comparable to transurethral resection

A new interventional radiology treatment that blocks blood supply to men's enlarged prostate glands shows comparable clinical results to transurethral resection of the prostate (or TURP), considered the gold standard (or most common) treatment. However, this minimally invasive treatment-prostatic artery embolization-has none of the risks associated with TURP, such as sexual dysfunction, urinary incontinence, blood loss and retrograde ejaculation, noted researchers at the Society of Interventional Radiology's 36th Annual Scientific Meeting in Chicago.

30 Mar 2011

First clinical use of GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface on lower profile delivery system

W. L. Gore & Associates (Gore) today reported the first clinical use in the U.S. of the GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface on a lower profile delivery system. The GORE VIABAHN Device is designed to percutaneously treat Superficial Femoral Artery (SFA) and iliac peripheral artery disease by relining the native vessel.

21 Mar 2011

DMC CVI completes the first two transcatheter aortic valve implants in Michigan

The Detroit Medical Center (DMC) Cardiovascular Institute (CVI) has completed the first two transcatheter aortic valve implants (TAVI) ever achieved in Michigan. The procedures are a part of CVI's participation in the Medtronic CoreValve® U.S. Clinical Trial. This multi-state trial will evaluate a new, non-surgical alternative to open-heart surgery for patients with severe aortic stenosis.

2 Mar 2011

Investigational heart valve implanted in patient through small puncture hole in leg

Physicians at the Methodist DeBakey Heart & Vascular Center in Houston implanted a new investigational heart valve in a patient through a small puncture hole in the leg.

21 Feb 2011

FDA approves GORE VIABAHN device to treat peripheral artery disease

W. L. Gore & Associates today announced it has received FDA approval for the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface on a lower profile delivery system.

17 Feb 2011

IDEV announces release of SUPERA stent data from Leipzig Registry

IDEV Technologies, Incorporated, an innovative leader in the development and commercialization of minimally invasive medical technologies, today announced the release of two-year European data from the prominent Leipzig Registry, which tracks patients treated with the SUPERA wire interwoven nitinol stent.

27 Jan 2011

Methodist DeBakey Heart & Vascular Center chosen for critical percutaneous heart valve study

The Methodist DeBakey Heart & Vascular Center was chosen today as a site for a critical percutaneous heart valve study. As part of the research study, Methodist physicians will replace diseased cardiac valves through a single, tiny puncture hole in the research subject's groin.

24 Jan 2011

Pervasis to present PVS-10200 interim data from Phase 1/2 PAD clinical study at IC3D

Pervasis Therapeutics, Inc. today announced it will present interim data from the company's Phase 1/2 clinical study of PVS-10200, an investigational cell-based therapy under development to prevent restenosis in patients with peripheral arterial disease (PAD) who undergo an angioplasty and stent procedure in the superficial femoral artery.

21 Jan 2011

Pervasis pursues matrix-embedded endothelial cell-based therapy to target and regulate cell stroma

Pervasis Therapeutics, Inc. today announced that the company is pursuing a matrix-embedded endothelial cell-based therapy (PVS-30200) to target and regulate cell stroma (the tumor environment or "ecosystem" that is comprised of various supporting cell types distinct from cancer cells) in order to prevent key processes that play a role in advancing solid tumor growth and metastasis.

20 Jan 2011